Protocol No
NRG-BR008-HERO
Phase
III
Summary
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Description
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Participating Institutions
Drexel Town Center
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov